NEKTAR THERAPEUTICS (NASDAQ:NKTR)
8.64
0.09 (1.03%)
| NEKTAR THERAPEUTICS (NASDAQ:NKTR) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $8.73 | 52 Week High | $10.64 | ||
| Open | $8.69 | 52 Week Low | $2.93 | ||
| Day High | $8.82 | P/E | N/A | ||
| Day Low | $8.57 | EPS | $-0.19 | ||
| Volume | 493,290 | ||||
| More NKTR Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| AZN | 5 | PFE | 3 |
| TNK | 1 | AGYS | 1 |
| CGX | 1 | EP | 1 |
| HBIO | 1 | LIZ | 1 |
| NSIT | 1 | RMTI | 1 |
| TRMA | 1 | ZBRA | 1 |
Entities who have mentioned NKTR
- Matrix USA | View Related Stories »
- Morgan Joseph | View Related Stories »
- UBS | View Related Stories »
- Daniel Loeb | View Related Stories »
- Goldman Sachs | View Related Stories »
- Merrill Lynch | View Related Stories »
- Piper Jaffray | View Related Stories »
- Lehman Brothers | View Related Stories »
- Wedbush Morgan | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
- ADP Employment Report | View Related Stories »
- Federal Open Market Committee | View Related Stories »
- Crude Oil | View Related Stories »
- Trading Radar | View Related Stories »
- Layoffs | View Related Stories »
- Vanguard | View Related Stories »
- Citi | View Related Stories »
- Scopia Capital | View Related Stories »
- Notable Mergers and Acquisitions | View Related Stories »
- William Blair | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Barclays | View Related Stories »
- Brean Murray Carret & Co. | View Related Stories »
- Boenning & Scattergood | View Related Stories »
View All Major News StreetInsider.com Major News for NKTR
- Nektar Therapeutics (NKTR) Enters Worldwide Agreement With AstraZeneca (AZN) for NKTR-118 and NKTR-119
- Nektar Therapeutics (NKTR) Tops Q2 View By 6c
- Nektar (NKTR) Reports Better-Than-Expected Q1 Loss of $0.34
View All ReportsStreetInsider.com Reports on NKTR
- Morgan Joseph Reiterates a 'Buy' on Nektar Therapeutics (NKTR)
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Hapoalim Securities Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; Ongoing Programs to Help Drive Share Price
- BMO Capital Upgrades Nektar Therapeutics (NKTR) to Outperform
- Morgan Joseph Reiterates a 'Buy' on Nektar Technology (NKTR); Sees Substantial Added Value From AstraZeneca Deal
View All Press ReleasesCompany Press Releases on NKTR
- Nektar Therapeutics Reports Third Quarter 2009 Financial Results
- Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
- Alexandria Real Estate Equities, Inc. Provides Update
- Nektar Completes Enrollment Ahead of Schedule in Phase 2 Clinical Trial Evaluating NKTR-102 in Patients with Platinum-Resistant Ovarian Cancer
- Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego
StreetInsider Reports on NKTR by Category
View All BlogsBlogs on NKTR
- Thursday Options Recap
- Progenics: Investors Are Right To Be Wary
- AstraZeneca: Nektar Deal to Add Value
- Financing Activity for Biotech Deals Heats Up
- 15 Overvalued Small Caps from Russell 2000
View All FilingsSEC Filings on NKTR
- Form 4 NEKTAR THERAPEUTICS For: Nov 18 Filed by: Labrucherie Gil M
- Form 4 NEKTAR THERAPEUTICS For: Nov 18 Filed by: Nicholson John
- Form 4 NEKTAR THERAPEUTICS For: Nov 18 Filed by: CHOWRIRA BHARAT M
- Form 8-K NEKTAR THERAPEUTICS For: Nov 04
- Form 8-K NEKTAR THERAPEUTICS For: Oct 08
Comments on recent NKTR articles
Comments on NKTR
No comments are currently available.
on Apr 9, 2008
at 10:11 AM MNKD Sudden decline Recent studies indicating increased lung Cancer with inhaled insulin resulted in $3 + drop in stock price, a great buy opportunity for long term potential of this company!
Article: Nektar Therapeutics (NKTR) Fall Likely To Hurt Mannkind Corp (MNKD)